Suprachoroidally injected pharmacological agents for the treatment of chorio‐retinal diseases: a targeted approach
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Delivery of pharmaceuticals to the posterior segment presents challenges that arise from the anatomy and clearance pharmacokinetics of the eye. Systemic and several local administration options [topical, periocular, intravitreal (IVT) and subretinal] are in clinical use, each with a unique benefit to risk profile shaped by factors including the administered agent, frequency of dosing, achievable pharmaceutical concentrations within posterior segment structures versus elsewhere in the eye or the body, invasiveness of the procedure and the inherent challenges with some administration methods. The use of the suprachoroidal space (SCS), which is the region between the sclera and the choroid, is being explored as a potential approach to target pharmacotherapies to the posterior segment via a minimally invasive injection procedure. Preclinical data on agents such as vascular endothelial growth factor inhibitors and triamcinolone acetonide (TA) indicate that administration via suprachoroidal injection results in more posterior distribution of the pharmacologic agent, with higher exposure to the sclera, choroid, retinal pigment epithelium cells and retina, and lesser exposure to the anterior segment, than observed with IVT administration. Based in part on these findings, clinical trials have explored the efficacy and safety of suprachoroidal administration of pharmacologic therapies in conditions affecting the posterior segment. Data on a proprietary formulation of TA administered by suprachoroidal injection show improvement in anatomic and visual outcomes in subjects with noninfectious uveitis, with the potential to mitigate the known risks of cataract and increased intraocular pressure (IOP) associated with the use of intraocular corticosteroids. Suprachoroidal administration appears to be a promising treatment modality and is also in the early stages of investigation for other possible applications, such as injection of antiglaucoma agents into the anterior SCS for long‐lasting control of elevated IOP, and as a mode of delivery for gene‐ or cell‐based therapies for retinal disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Diabetic retinopathy: current understanding, mechanisms, and treatment strategies
Duh, E. J., Sun, J. K., & Stitt, A. W. (2017) · JCI Insight · doi:10.1172/jci.insight.93751 · Cited by 1,057 · cited 1×
“Injecting fluid between RPE and photoreceptors, which temporarily creates a subretinal bleb, is an uncommon surgical procedure, and much is still to be learned about the efficacy and safety of gene therapies administered in this manner (Duncan 2017).”
BackgroundGhasemi Falavarjani, K., & Nguyen, Q. D. (2013) · Eye · doi:10.1038/eye.2013.107 · Cited by 982 · cited 1×
“…vitreous have been associated with infre quent adverse events such as endophthalmitis, retinal tear and retinal detachment, whether using anti-VEGF agents or corticosteroids (Fasolino et al. 2007; Scott et al. 2009; Falavarjani & Nguyen 2013; Karabag et al. 2015; Lai et al. 2015; Fong & Chan 2017).”
BackgroundPharmacokinetic aspects of retinal drug delivery
del Amo, E. M., Rimpelä, A.-K., Heikkinen, E., Kari, O. K., Ramsay, E., Lajunen, T., Schmitt, M., Pelkonen, L., Bhattacharya, M., Richardson, D., et al. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.12.001 · Cited by 693
Suprachoroidal drug delivery to the back of the eye using hollow microneedles
Patel, S. R., Lin, A. S. P., Edelhauser, H. F., & Prausnitz, M. R. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0271-y · Cited by 330 · cited 1×
“Patel and colleagues demonstrated feasibility with injection of particle-containing suspensions in ex vivo animal and human eyes (Patel et al. 2011).”
BackgroundVisual Acuity after Retinal Gene Therapy for Choroideremia
Edwards, T. L., Jolly, J. K., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Black, G. C., Webster, A. R., Lotery, A. J., Holder, G. E., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1509501 · Cited by 195
Subretinal injection: a review on the novel route of therapeutic delivery for vitreoretinal diseases
Peng, Y., Tang, L., & Zhou, Y. (2017) · Ophthalmic Research · doi:10.1159/000479157 · Cited by 175 · cited 2×
“As a strategy for targeted delivery, subretinal injection of genetic material has the advantage of being available directly to the photoreceptors and RPE cells, providing potential for access to these cells for the treatment of disorders due to mutations in photoreceptor and/or RPE genes (Peng et al. 2017).”
BackgroundCannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment
Olsen, T. W., Feng, X., Wabner, K., Conston, S. R., Sierra, D. H., Folden, D. V., Smith, M. E., & Cameron, J. D. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.05.045 · Cited by 171 · cited 2×
“Animal studies have demonstrated feasibility of suprachoroidal administration of pharmaceuticals via surgical procedures that involved creation of a scleral incision, insertion of a catheter into the SCS and injection of a probemolecule or pharmaceutical followed by suturing of the scleral incision (Einmahl et al. 200…”
BackgroundOlsen, T. W., Feng, X., Wabner, K., Csaky, K., Pambuccian, S., & Cameron, J. D. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6291 · Cited by 106 · cited 2×
“Preclinical studies, discussed in detail below, have shown that a solution or suspension containing a pharmacological agent injected suprachoroidally appears to distribute within the sclera, choroid, RPE and retina (Olsen et al. 2011; Patel et al. 2012; Edelhauser et al. 2014).”
BackgroundPeden, M. C., Min, J., Meyers, C., Lukowski, Z., Li, Q., Boye, S. L., Levine, M., Hauswirth, W. W., Ratnakaram, R., Dawson, W., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017140 · Cited by 63
Cited by
Han, H., Li, S., Xu, M., Zhong, Y., Fan, W., Xu, J., Zhou, T., Ji, J., Ye, J., & Yao, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114770 · Cited by 322
Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis
Yeh, S., Khurana, R. N., Shah, M., Henry, C. R., Wang, R. C., Kissner, J. M., Ciulla, T. A., & Noronha, G. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.01.006 · Cited by 191
Self-citationHan, I. C., Cheng, J. L., Burnight, E. R., Ralston, C. L., Fick, J. L., Thomsen, G. J., Tovar, E. F., Russell, S. R., Sohn, E. H., Mullins, R. F., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.043 · Cited by 60
Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema
Barakat, M. R., Wykoff, C. C., Gonzalez, V., Hu, A., Marcus, D., Zavaleta, E., & Ciulla, T. A. (2021) · Ophthalmology Retina · doi:10.1016/j.oret.2020.08.007 · Cited by 55
Self-citation
Metadata
- Authors
- Habot‐Wilner, Z., Noronha, G., & Wykoff, C. C.
- Venue
- Acta Ophthalmologica
- Publisher
- Wiley
- Published
- 2019-01-31
- Volume
- 97
- Issue
- 5
- Pages
- 460-472
- ISSN
- 0001-639X (ISSN-L)
- 1755-375X
- 1755-3768
- OpenAlex
- W2914892298
- Cited by
- 83
- References
- 10
- FWCI
- 8.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.